Hepatitis C virus reinfection in patients on haemodialysis after achieving sustained virologic response with antiviral treatment

Chen Hua Liu, Cheng Yuan Peng, Wei Yu Kao, Sheng Shun Yang, Yu Lueng Shih, Chin Lin Lin, Meng Kun Tsai, Chih Yuan Lee, Chun Chao Chang, Jo Hsuan Wu, Chun Jen Liu, Tung Hung Su, Tai Chung Tseng, Pei Jer Chen, Jia Horng Kao

研究成果: 雜誌貢獻文章同行評審

1 引文 斯高帕斯(Scopus)

摘要

Background: Data are limited regarding the risk of hepatitis C virus (HCV) reinfection after treatment-induced sustained virologic response (SVR) in patients on haemodialysis. Aims: To assess the risk of HCV reinfection among patients on haemodialysis with treatment-induced SVR. Methods: Patients on haemodialysis patients who achieved SVR12 with interferon (IFN) or direct-acting antiviral (DAA)-based treatment received follow-up at SVR24 and then biannually with HCV RNA measurements. HCV reinfection was defined as the resurgence of viremia by different viral strains beyond SVR12. The low-risk general population who achieved SVR12 and who underwent the same post-SVR12 surveillance served as the reference group. Crude reinfection rates per 100 person-years (PYs) were calculated. Multivariate Cox regression analysis was performed to estimate the relative risk of HCV reinfection between the two groups. Results: We recruited 374 patients on haemodialysis and 1571 reference patients with a mean post-SVR12 follow-up of 4.7 and 6.1 years. All haemodialysis patients who achieved SVR12 also achieved SVR24. The incidence rates of HCV reinfection were 0.23 per 100 PYs (95% confidence interval [CI]: 0.09-0.59) in haemodialysis patients and 0.16 per 100 PYs (95% CI: 0.10-0.26) in the reference group. The risk of HCV reinfection in patients on haemodialysis was comparable to that in the reference patients (hazard ratio [HR]: 1.39; 95% CI: 0.44-4.38, P = 0.57). Conclusions: The risk of HCV reinfection in patients on haemodialysis who achieve SVR12 is low and comparable to that in the low-risk general population. HCV microelimination in this special population is feasible once universal screening and scaled-up treatment are implemented.
原文英語
頁(從 - 到)434-445
頁數12
期刊Alimentary Pharmacology and Therapeutics
55
發行號4
DOIs
出版狀態已發佈 - 2月 2022

ASJC Scopus subject areas

  • 肝病
  • 消化內科
  • 藥學(醫學)

指紋

深入研究「Hepatitis C virus reinfection in patients on haemodialysis after achieving sustained virologic response with antiviral treatment」主題。共同形成了獨特的指紋。

引用此